ArticleJournal of cosmetic dermatology2025
Novel Electrotrichogenic Device Promotes Hair Growth in Men With Androgenetic Alopecia: A Pilot Study.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06994819 (Double-blind Randomized Controlled Clinical Trial Under Dermatological Monitoring on Skin Tolerability and Efficacy of the Niostem Headset on Hair Growth, Hair Loss and Hair Quality After 3 and 6 Months of Daily Use), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Double-blind Randomized Controlled Clinical Trial Under Dermatological Monitoring on Skin Tolerability and Efficacy of the Niostem Headset on Hair Growth, Hair Loss and Hair Quality After 3 and 6 Months of Daily Use
Who cites it
2 citing papers in PubMed.
- Efficacy, Safety, and Tolerability of a Wearable Electrotrichogenic Device in Men with Androgenetic Alopecia: A Randomized, Double-Blind, Sham-Controlled Trial.Dermatology and therapy · 2026Article
- Serum Granulysin Levels in Vitiligo and Alopecia Areata: A Potential Biomarker for Disease Activity and Dermoscopic Evaluation.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAndrogenetic alopecia (AGA) is the most common cause of hair loss globally, affecting millions of people, particularly men. Current treatments include FDA-approved drugs and devices, but many patients experience side effects or suboptimal results. The niostem device is a new, wearable device that delivers low-level electrical stimulation to promote hair growth. This pilot study aims to evaluate the efficacy and safety of the niostem device in male AGA patients.
methodsA total of 21 male patients with AGA used the niostem device daily for 30 min over 6 months. Participants had not used any anti-hair loss products within the 6 months preceding the start of the study. Hair density, thickness, and terminal hair counts were assessed at baseline, 3 months, and 6 months using trichoscopic measurements. Patient-reported outcomes were recorded, and adverse events were monitored.
resultsThe niostem device resulted in significant increases in hair count, with a 12% increase in total hair density at 3 months and a 19.3% increase at 6 months. Hair thickness also increased by 8.8% in 6 months. Terminal hair density improved significantly over time, with visible hair growth observed in the participants. No adverse events were reported.
conclusionsThe niostem device demonstrated a significant increase in hair density and hair thickness in male AGA patients, with no adverse effects. Further large-scale studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.